EndoBarrier® Therapy is the first endoscopically-delivered device therapy for people living with uncontrolled type 2 diabetes and obesity. EndoBarrier Therapy is a convenient and discreet treatment for people whose diabetes medications are no longer effective, who are at risk for serious health complications from their diabetes and/or excess weight and who want to avoid surgery or the progression to injectable therapy (some of the GLPs are weekly). This first-of-its-kind therapy is helping patients around the world fight their battle against type 2 diabetes and obesity while providing a pathway to a healthier lifestyle.
Clinical data suggest that treatment with EndoBarrier Therapy affects key gastrointestinal hormones involved in insulin sensitivity, glucose metabolism, satiety and food intake.1 Additionally, in clinical studies, EndoBarrier Therapy has also been shown to improve cardiometabolic risks.2,3
EndoBarrier is approved and available in multiple countries outside the U.S.; and GI Dynamics is conducting a pivotal clinical trial of EndoBarrier (the ENDO Trial) in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. If you are interested in learning more about the ENDO Trial, please visit www.endobarriertrial.com
EndoBarrier® is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. EndoBarrier® currently has the CE mark and is approved for commercial use in Australia, as well as by a growing number of regulatory bodies in South America and the Middle East.
In clinical studies, the most common complications were nausea, vomiting and upper abdominal pain. Other risks—which are not likely but could occur—include infection, tissue trauma, bleeding and device blockage.
If you are pregnant or are thinking about becoming pregnant, EndoBarrier® Therapy is not recommended.
As with any medical procedure, it is important to discuss with your doctor the potential risks and benefits as they apply to your health to help determine if EndoBarrier Therapy might be right for you.
1 de Jonge C, et al, “Endoscopic Duodenal-Jejunal Bypass Liner Rapidly Improves Type 2 Diabetes.”, Obesity Surgery, Sept. 2013, Volume 23, Issue 9, pp 1354-1360
2 Moura, GHD, et al, “One Year Results of an Endoscopic, Duodenal-Jejunal Exclusion Device for Weight Loss and Control of Type 2 Diabetes.” DT&T, February 2012, vol 14, no. 2: 183-189.
3 Escalona, A., et al, “Weight Loss and Metabolic Improvement in Morbidly Obese Subjects Implanted for 1 Year With an Endoscopic Duodenal-Jejunal Bypass Liner.” Annals of Surgery, June 2012, Vol 255, Issue 6, p 1080-1085.